AKBA - Akebia Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
292,602
292,602
213,578
295,307
335,001
Cost of revenue
84,796
84,796
153,394
295,908
145,336
Gross profit
207,806
207,806
60,184
-601
189,665
Operating expenses
Research development
129,114
129,114
147,852
218,485
322,969
Selling general and administrative
141,874
138,699
174,161
153,947
149,455
Total operating expenses
270,988
270,988
325,502
375,841
475,953
Operating income or loss
-63,182
-63,182
-265,318
-376,442
-286,288
Interest expense
15,687
15,687
-
-
-
Total other income/expenses net
-13,693
-29,380
-17,522
-7,015
-2
Income before tax
-92,562
-92,562
-282,840
-383,457
-286,290
Income tax expense
0
0
0
0
-6,631
Income from continuing operations
-92,562
-92,562
-282,840
-383,457
-279,659
Net income
-92,562
-92,562
-282,840
-383,457
-279,659
Net income available to common shareholders
-92,562
-92,562
-282,840
-383,457
-279,659
Basic EPS
-
-
-1.70
-2.77
-2.36
Diluted EPS
-
-
-1.70
-2.77
-2.36
Basic average shares
-
-
165,950
138,463
118,396
Diluted average shares
-
-
165,950
138,463
118,396
EBITDA
-
-63,182
-265,318
-376,442
-286,288